Recombinant Human B7-2/CD86 Fc Chimera Protein, CF

Catalog #: 141-B2
5 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
141-B2-100

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Citations (5)

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human B7-2/CD86 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to induce IL-2 secretion by Jurkat human acute T cell leukemia cells. Freeman, G.J. et al. (1993) Science 262:909. The ED₅₀ for this effect is 0.2‑0.8 µg/mL in the presence of PHA.

Source

Mouse myeloma cell line, NS0-derived human B7-2/CD86 protein

Human B7-2 (Leu20-His239) Accession # AAB03814	DIEGRMD	Human IgG₁ (Pro100-Lys330)	6-His tag
N-terminus			C-terminus

Accession #

AAB03814

N-terminal Sequence
Analysis

Leu20

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

52.7 kDa (monomer)

SDS-PAGE

85-95 kDa, reducing conditions

Product Datasheets

141-B2

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

141-B2

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: B7-2/CD86

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (4-7), as well as on vascular endothelial cells (8). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3-5, 7, 9-11). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3-5, 7, 9, 10). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (12). B7-2 is expressed earlier than B7-1 following APC activation (6), and both proteins bind with higher affinity to CTLA-4 than to CD28 (10). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (13). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (14). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (15).

References

Greenwald, R.J. et al. (2005) Annu. Rev. Immunol. 23:515.
Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
Freeman, G.J. et al. (1993) Science 262:909.
Azuma, M. et al. (1993) Nature 366:76.
Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.
Lenschow, D.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:11054.
Hathcock, K.S. et al. (1993) Science 262:905.
Seino, K. et al. (1995) Int. Immunol. 7:1331.
Chen, C. et al. (1994) J. Immunol. 152:4929.
Lanier, L.L. et al. (1995) J. Immunol. 154:97.
Rudd, C.E. et al. (2009) Immunol. Rev. 229:12.
Wing, K. et al. (2011) Trends Immunol. 32:428.
Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
Kuchroo, V.K. et al. (1995) Cell 80:707.
Short, J.J. et al. (2006) Virus Res. 122:144.

Entrez Gene IDs

942 (Human); 12524 (Mouse); 56822 (Rat); 102147235 (Cynomolgus Monkey)

Alternate Names

Activation B7-2 antigen; B70; B7-2 antigen; B72; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; CD28LG2B7-2 antigen); CD86 antigen; CD86 molecule; CD86; CTLA-4 counter-receptor B7.2; FUN-1; LAB72; MGC34413; T-lymphocyte activation antigen CD86

Related Research Areas

Citations for Recombinant Human B7-2/CD86 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

The homodimer interfaces of costimulatory receptors B7 and CD28 control their engagement and pro-inflammatory signaling
Authors: Popugailo, A;Rotfogel, Z;Levy, M;Turgeman, O;Hillman, D;Levy, R;Arad, G;Shpilka, T;Kaempfer, R;
Journal of biomedical science
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture
An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome
Authors: H Sic, M Speletas, V Cornacchio, M Seidl, M Beibel, B Linghu, F Yang, E Sevdali, AE Germenis, EJ Oakeley, E Vangreveli, AW Sailer, E Traggiai, H Gram, H Eibel
Front Immunol, 2017-12-15;8(0):1824.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding
Authors: Lutz Jermutus
J. Immunol., 2016-11-23;0(0):.
Applications: Bioassay
Genomic landscape of cutaneous T cell lymphoma.
Authors: Choi J, Goh G, Walradt T, Hong B, Bunick C, Chen K, Bjornson R, Maman Y, Wang T, Tordoff J, Carlson K, Overton J, Liu K, Lewis J, Devine L, Barbarotta L, Foss F, Subtil A, Vonderheid E, Edelson R, Schatz D, Boggon T, Girardi M, Lifton R
Nat Genet, 2015-07-20;47(9):1011-9.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm.
Authors: Sakthivel P, Shively V, Kakoulidou M
J. Intern. Med., 2007-04-01;261(4):399-407.
Applications: ELISA (Standard)